Finally, from a therapeutic point of view, compounds specific to CRABP1 that do not bind to RARs/RXRs would be better candidates as therapeutics for targeting CRABP1 to selectively intercept certain biological processes, such as inhibiting cancer cell growth and improving survival/function. The gene discussed is CRABP1; the disease is cancer.